Recent Updates
Recently added Catalysts
VOR Positive Sentiment

Vor Bio To Participate in Upcoming September Conferences

Key Takeaway: Vor Bio announced its participation in several upcoming investor conferences in September 2026. The conferences include the Wells Fargo 21st Annual Healthcare Conference and the Citi Biopharma Back to School Conference, among others. These events will feature fireside chats and one-on-one meetings, providing opportunities for investor engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Vor Bio is actively participating in multiple investor conferences.
  • The company is focused on advancing its novel treatment for autoimmune diseases.
  • Management engagement at these conferences can enhance investor interest.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease

Full Press Release Details

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the following investor conferences:
• Wells Fargo 21st Annual Healthcare Conference
Forum: Fireside Chat and 1x1 Meetings Date: Tuesday, September 8th Presentation Time: 8:00AM ET
• Citi’s 2026 Biopharma Back to School Conference
Forum: Fireside Chat and 1x1 Meetings Date: Wednesday, September 9th Presentation Time: 11:20AM ET
• Morgan Stanley 24th Annual Global Healthcare Conference
Forum: 1x1 Meetings Date: Monday, September 14th
• Baird’s 2026 Global Healthcare Conference
Forum: Presentation and 1x1 Meetings Date: Tuesday, September 15th Presentation Time: 9:05AM ET
• Stifel’s 2026 Virtual Immunology and Inflammation Forum
Forum: Presentation and 1x1 Meetings Date: Wednesday, September 23rd Presentation Time: 11:30AM ET
A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.
About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com. Vor Bio routinely posts information that may be important to investors in the “Investors” section of its website. The Company encourages investors to consult that section of its website regularly.

Frequently Asked Questions

What conferences will Vor Bio participate in September 2026?

Vor Bio will participate in the Wells Fargo, Citi, Morgan Stanley, Baird, and Stifel conferences.

What is Vor Bio's focus in biotechnology?

Vor Bio focuses on transforming the treatment of autoimmune diseases.

How can investors access Vor Bio's presentations?

Investors can access live webcasts of the presentations on Vor Bio's website.

What is telitacicept?

Telitacicept is a novel dual-target fusion protein being developed by Vor Bio.

Last updated: Sep 1, 2026